Issue

2022

Copyright (c) 2022 Christian German Ospina Pérez, Ivan David Lozada Martínez, José Carlos Posada Viana, Bernarda Cuadrado Cano

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Factors associated with pancreatitis after endoscopic retrograted cholangiopancreatography: a single center's experience in the Colombian Caribbean

https://doi.org/10.17081/innosa.147
Christian German Ospina Pérez
Universidad de Cartagena
Ivan David Lozada Martínez
Universidad de Cartagena
José Carlos Posada Viana
Universidad de Cartagena
Bernarda Cuadrado Cano
Universidad de Cartagena

Corresponding Author(s) : Ivan David Lozada Martínez

ivandavidloma@gmail.com

Ciencia e Innovación en Salud, 2022

Abstract

Background: Currently, endoscopic retrograde cholangiopancreatography (ERCP) is one of the most useful studies in the therapeutic approach to pancreato-biliary diseases. However, being an invasive procedure, it carries a certain risk of complications, such as pancreatitis. In Latin America, there is a great lack of epidemiological research on factors associated with the development of post-ERCP pancreatitis. Methods: Retrospective, quantitative and analytical case-control research, where patients older than 18 years who had undergone ERCP between 2013-2018 were included. Controls were chosen in a 2:1 ratio, evaluating sociodemographic, clinical, paraclinical, surgical and post-surgical variables. Results:  A total of 180 ERCPs were identified, 32 cases of post-ERCP pancreatitis were detected (17.8%), and 64 patients were taken as controls. In the sample, female sex, pre-surgical ASA grade I, and pre-surgical diagnosis of predominantly lithiasis prevailed. When assessing risk by crude OR, there was an association of post-ERCP pancreatitis with the presence of abdominal pain (OR 4.2; 95% CI 1.6-10.7), pancreatic pain (OR 3.2; 95% CI 2. 3-4.3), vomiting (OR 4.2; 95% CI 1.1-15.6), abdominal distension (OR 8.3, 95% CI 2.4-10.4), lipase > 948 IU/L (OR 8.3; 95% CI 2.4-10.4) and amylase greater than 350 IU/L (OR 1.4; 95% CI 5.0-20.4). Conclusions:   Factors associated with post-ERCP pancreatitis were abdominal pain, pancreatic pain, vomiting, abdominal distension, elevated lipase and amylase

Keywords

Pancreatitis, Endoscopic Retrograted Cholangiopancreatography, Endoscopy, Diagnostic Techniques and Procedures, Risk Factors
1.
Ospina Pérez CG, Lozada Martínez ID, Posada Viana JC, Cuadrado Cano B. Factors associated with pancreatitis after endoscopic retrograted cholangiopancreatography: a single center’s experience in the Colombian Caribbean. Ciencia e Innovación en Salud [Internet]. 2022 Mar. 16 [cited 2024 Nov. 25];. Available from: https://revistas.unisimon.edu.co/index.php/innovacionsalud/article/view/5271
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  • Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18.
  • Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011; 73(2):275-82.
  • Tsuchiya T, Itoi T, Sofuni A, Itokawa F, Kurihara T, Ishii K, et al. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial. J Hepatobiliary Pancreat Surg 2007; 14:302-7.
  • Lukić S, Alempijević T, Jovanović I, Popović D, Krstić M, Ugljesić M. Occurrence and risk factor for development of pancreatitis and asymptomatic hyperamylasemia following endoscopic retrograde cholangiopancreatography--our experiences. Acta Chir Iugosl. 2008; 55(1):17-24.
  • Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004; 59:845-64.
  • Cha SW, Leung WD, Lehman GA, Watkins JL, McHenry L, Fogel EL, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study. Gastrointest Endosc. 2013; 77(2):209-16.
  • Mine T, Morizane T, Kawaguchi Y, Akashi R, Hanada K, Ito T, et al. Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol. 2017; 52(9):1013-1022.
  • Hwang HJ, Guidi M, Curvale C, Lasa J, Matano R. Pancreatitis post-CPRE: ¿precorte temprano o prótesis pancreática?: ensayo aleatorizado, multicéntrico y análisis de costo-efectividad. Rev Esp Enferm Dig. 2017; 109(3):174-179.
  • Murillo Zolezzi A, Vidal González P, Cárdenas Salomon C, Robles Castillo J, Sarue Saed N. Pancreatitis aguda severa temprana postcolangiopancreatografía retrógrada endoscópica, presentación de un caso. Cirugia Endoscopica. 2009; 10(1):40-44.
  • Del Castillo Rangel FR, Arango Molano LA. Determinación de la frecuencia de hiperamilasemia y pancreatitis en pacientes llevados a colangiopancreatografía retrógrada endoscópica. Rev Col Gastroenterol. 2017; 32(3):223-229.
  • Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383–93.
  • Ministerio de Salud de Colombia. Resolución 8430 de 1993 [Internet]. [Consultado 28 Jun 2021]. Disponible en: https://www.minsalud.gov.co/salud/Lists/Normatividad%20%20Salud/DispForm.aspx?ID=2110&ContentTypeId=0x0100A08A4A1DF8E9D448BEF600BFAC0E7622
  • Asociación Médica Mundial. Declaración de Helsinki de la AMM – principios éticos para las investigaciones médicas en seres humanos [Internet]. [Consultado 28 Jun 2021]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
  • Cevallos V. Sensibilidad y especificidad de la amilasemia como ayuda diagnóstica inicial para pancreatitis aguda en pacientes que acudieron por dolor abdominal agudo al servicio de emergencia del Hospital Vozandes – Quito entre los meses de julio del año 2006 y junio del año 2007. Rev Médica la Univ Costa Rica. 2009; 3(1):96–8.
  • Herrera MF, Jácome GG, Llumipanta IE. Utilidad de amilasa y lipasa en diagnóstico y tratamiento de dolor abdominal agudo. Quim Cent. 2017; 6(01):11–9.
  • Ojo AS. Pancreatic Duct Variations and the Risk of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Cureus. 2020; 12(9):e10445.
  • Pekgöz M. Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment. World J Gastroenterol. 2019; 25(29):4019-4042.
  • Maruyama H, Shiba M, Ishikawa-Kakiya Y, Kato K, Ominami M, Fukunaga S, et al. Positive correlation between pancreatic volume and post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2020; 35(5):769-776.
  • Lyu Y, Cheng Y, Wang B, Xu Y, Du W. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018; 18(1):106.
  • Garg R, Mohan BP, Krishnamoorthi R, Rustagi T. Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis. Indian J Gastroenterol. 2018; 37(2):120-126.
  • Vadalà di Prampero SF, Faleschini G, Panic N, Bulajic M. Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review. Eur J Gastroenterol Hepatol. 2016; 28(12):1415-1424.
  • Zhou W, Li Y, Zhang Q, Li X, Meng W, Zhang L, et al. Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis: a retrospective analysis of 7,168 cases. Pancreatology. 2011; 11(4):399-405.
Read More
Author biographies is not available.

Most read articles by the same author(s)